These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37181967)

  • 21. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
    Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
    Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors of breast cancer recurrence in pathologic complete response achieved by patients following neoadjuvant chemotherapy: a single-center retrospective study.
    Choi JY; Woen D; Jang SY; Lee H; Shin DS; Kwak Y; Lee H; Chae BJ; Yu J; Lee JE; Kim SW; Nam SJ; Ryu JM
    Front Oncol; 2023; 13():1230310. PubMed ID: 37849818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
    J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy.
    Shi Z; Liu Y; Zhang S; Cai S; Liu X; Meng J; Zhang J
    Discov Oncol; 2023 Apr; 14(1):49. PubMed ID: 37099044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Outcomes Among Major Breast Cancer Subtypes After Neoadjuvant Chemotherapy: Impact on Breast Cancer Recurrence and Survival.
    Orsaria P; Grasso A; Ippolito E; Pantano F; Sammarra M; Altomare C; Cagli B; Costa F; Perrone G; Soponaru G; Caggiati L; Vanni G; Buonomo OC; Altomare V
    Anticancer Res; 2021 May; 41(5):2697-2709. PubMed ID: 33952501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
    Giacchetti S; Hamy AS; Delaloge S; Brain E; Berger F; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Saghatchian M; Lerebours F; Mazouni C; Tembo O; Espié M; Reyal F; Marty M; Asselain B; Pierga JY
    Eur J Cancer; 2017 Apr; 75():323-332. PubMed ID: 28279941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
    Fountzilas G; Dafni U; Bobos M; Batistatou A; Kotoula V; Trihia H; Malamou-Mitsi V; Miliaras S; Chrisafi S; Papadopoulos S; Sotiropoulou M; Filippidis T; Gogas H; Koletsa T; Bafaloukos D; Televantou D; Kalogeras KT; Pectasides D; Skarlos DV; Koutras A; Dimopoulos MA
    PLoS One; 2012; 7(6):e37946. PubMed ID: 22679488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
    Cherifi F; Da Silva A; Johnson A; Blanc-Fournier C; Abramovici O; Broyelle A; Levy C; Allouache D; Hrab I; Segura C; Morel A; Villemin M; Boscher C; Dubot-Poitelon C; Rottier P; Lequesne J; Emile G
    BMC Cancer; 2022 Oct; 22(1):1081. PubMed ID: 36266623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
    Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
    Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia.
    Al-Saleh K; Salah T; Arafah M; Husain S; Al-Rikabi A; Abd El-Aziz N
    PLoS One; 2021; 16(3):e0247802. PubMed ID: 33667252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The diagnostic accuracy of magnetic resonance imaging in predicting pathologic complete response after neoadjuvant chemotherapy in patients with different molecular subtypes of breast cancer.
    Zhang X; Wang D; Liu Z; Wang Z; Li Q; Xu H; Zhang B; Liu T; Jin F
    Quant Imaging Med Surg; 2020 Jan; 10(1):197-210. PubMed ID: 31956542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of hormone receptor, HER2, and Ki-67 status conversions on survival after neoadjuvant chemotherapy in breast cancer patients: a retrospective study.
    Chen Y; Liu X; Yu K; Sun X; Xu S; Qiu P; Lv Z; Zhang X; Guo A; Xu Y
    Ann Transl Med; 2022 Jan; 10(2):93. PubMed ID: 35282081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer.
    Qiao W; Guo W; Liu Q; Guo X; Deng M
    Ann Diagn Pathol; 2023 Jun; 64():152125. PubMed ID: 36822053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
    Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.
    Whitworth PW; Beitsch PD; Pellicane JV; Baron PL; Lee LA; Dul CL; Murray MK; Gittleman MA; Budway RJ; Rahman RL; Kelemen PR; Dooley WC; Rock DT; Cowan KH; Lesnikoski BA; Barone JL; Ashikari AY; Dupree BB; Wang S; Menicucci AR; Yoder EB; Finn C; Corcoran K; Blumencranz LE; Audeh W;
    JCO Precis Oncol; 2022 Apr; 6(1):e2100463. PubMed ID: 35476550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer].
    Wang Y; Zhang S; Zhang H; Liang L; Xu L; Cheng YJ; Duan XN; Liu YH; Li T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):853-862. PubMed ID: 36241228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
    Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
    Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
    Gao ZH; Li CX; Liu M; Jiang JY
    BMC Cancer; 2020 Nov; 20(1):1150. PubMed ID: 33238978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.